MURRIETA, CA--(Marketwire - November 12, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today issued a comment from Vera Leonard, chief executive officer of the company, regarding the recent disclosure that CLX expects to close the acquisition of the ThyroTest® product through the issuance of preferred stock and a note in the amount of $750,000.